precision neurology

A clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases

Welcome to ESCAPE, where we’re passionate about making a meaningful impact on patients suffering from CNS disorders—and where we believe genetics is key to achieving that goal. Our pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders; ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have a LRRK2 G2019S variant; and an Alzheimer's disease program targeting ApoE4. Our programs aim to improve the lives of patients suffering from Alzheimer's disease, Parkinson's disease, and CNS lysosomal storage disorders.

Diversified pipeline with
3 small molecules

MORE

NOW IN PHASE 1 MULTIPLE ASCENDING DOSE TRIAL: ESB1609 (AN S1P5 SELECTIVE AGONIST)

MORE

Now in IND-Enabling Studies: ESB5070 (A LRRK2 KINASE INHIBITOR)

MORE

An approach that increases the probability of success

Precision therapies targeting specific genetic populations have already come to market for other difficult-to-treat disease areas, such as cancer.

MORE